Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.

Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ.

Blood. 2004 Sep 1;104(5):1559-64. Epub 2004 May 11.

2.

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.

Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, Leithaeuser M, Hofmeister N, Junghanss C, Casper J, Hartung G, Holler E, Freund M.

Bone Marrow Transplant. 2005 May;35(10):1003-10.

PMID:
15806135
3.

Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.

Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, Chiu M, Boulad F, Castro-Malaspina HR, Heller G, Jakubowski AA, O'Reilly RJ, Small TN, Young JW, Kernan NA.

Bone Marrow Transplant. 2007 Sep;40(5):481-6. Epub 2007 Jul 9.

PMID:
17618322
4.

Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.

Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, Kahl C, Junghanss C, Hartung G, Casper J, Uharek L, Holler E, Freund M.

Bone Marrow Transplant. 2006 Sep;38(6):445-51.

PMID:
16951692
5.

Daclizumab for children with corticosteroid refractory graft-versus-host disease.

Teachey DT, Bickert B, Bunin N.

Bone Marrow Transplant. 2006 Jan;37(1):95-9.

PMID:
16247417
6.

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.

Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F; Phase III Daclizumab Study Group.

Transplantation. 2001 Sep 15;72(5):839-45.

PMID:
11571447
7.

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.

Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S.

Blood. 2000 Jan 1;95(1):83-9.

8.

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.

Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG.

Br J Haematol. 2001 Mar;112(3):820-3.

PMID:
11260089
9.

Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.

Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ.

J Pediatr Hematol Oncol. 2009 Jun;31(6):456-61. doi: 10.1097/MPH.0b013e31819daf60.

PMID:
19648797
10.
11.

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.

Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R.

Br J Haematol. 2004 Mar;124(6):777-86.

PMID:
15009066
12.

Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.

Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.

Liver Transpl. 2005 Jan;11(1):61-7.

13.

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.

Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, Atra A, Ortin M, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S.

Bone Marrow Transplant. 2003 Jul;32(2):165-70.

PMID:
12838281
14.

Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.

Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, Lioure B, Michel G, Burdach S, Kolb HJ, et al.

Transplantation. 1995 Nov 15;60(9):939-42.

PMID:
7491697
15.

Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10)

Hervé P, Wijdenes J, Bergerat JP, Bordigoni P, Milpied N, Cahn JY, Clément C, Béliard R, Morel-Fourrier B, Racadot E, et al.

Blood. 1990 Feb 15;75(4):1017-23.

16.

Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.

Bay JO, Dhédin N, Goerner M, Vannier JP, Marie-Cardine A, Stamatoullas A, Jouet JP, Yakoub-Agha I, Tabrizi R, Faucher C, Diez-Martin JL, Nunez G, Parody R, Milpied N, Espérou H, Garban F, Galambrun C, Kwiatkovski F, Darlavoix I, Zinaï A, Fischer A, Michallet M, Vernant JP.

Transplantation. 2005 Sep 27;80(6):782-8.

PMID:
16210965
18.

Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis.

Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vincenti F.

Transpl Int. 2000;13(2):151-9.

19.

Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.

Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1376-85. doi: 10.1016/j.bbmt.2009.06.017. Epub 2009 Aug 19.

20.

Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.

Lietz K, John R, Beniaminovitz A, Burke EM, Suciu-Foca N, Mancini DM, Edwards NM, Itescu S.

Transplantation. 2003 Mar 27;75(6):781-7.

PMID:
12660501

Supplemental Content

Support Center